Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGNDZ) Other financing activities (2020 - 2025)

Ligand Pharmaceuticals (LGNDZ) has disclosed Other financing activities for 5 consecutive years, with $617000.0 as the latest value for Q4 2025.

  • Quarterly Other financing activities rose 422.88% to $617000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $15.5 million through Dec 2025, up 3545.07% year-over-year, with the annual reading at $15.5 million for FY2025, 3545.07% up from the prior year.
  • Other financing activities hit $617000.0 in Q4 2025 for Ligand Pharmaceuticals, down from $14.8 million in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of $14.8 million in Q3 2025 to a low of -$121000.0 in Q1 2022.
  • Historically, Other financing activities has averaged $1.3 million across 4 years, with a median of $71000.0 in 2025.
  • Biggest YoY gain for Other financing activities was 6965.71% in 2025; the steepest drop was 96.49% in 2025.
  • Year by year, Other financing activities stood at $42000.0 in 2022, then soared by 2159.52% to $949000.0 in 2023, then plummeted by 87.57% to $118000.0 in 2024, then soared by 422.88% to $617000.0 in 2025.
  • Business Quant data shows Other financing activities for LGNDZ at $617000.0 in Q4 2025, $14.8 million in Q3 2025, and $2000.0 in Q2 2025.